OTTAWA, Nov. 14, 2011 /CNW/ - The Honourable Gary Goodyear, Minister of
State for Science and Technology today announced that leading
researchers from Canada and the United Kingdom will be working together
to address the challenge of antibiotic resistance with funding from the
Government of Canada and the UK Medical Research Council.
"Our Government is committed to protecting Canadians. Antibiotic
resistance is a serious challenge facing Canadians and our health care
system," said Minister Goodyear. "Our Government is pleased to support
this important collaborative effort to develop new strategies and tools
to protect Canadians from antibiotic resistant infections."
Two Canada-UK research teams have been funded through the Canada/UK
Partnership on Antibiotic Resistance, a collaboration between the
Canadian Institutes of Health Research and the UK Medical Research
Council. The partnership takes advantage of the strong academic and
clinical research strengths that exist in both Canada and the UK. Its
aim is to stimulate high quality research on innovative alternatives to
The two research teams are as follows:
A team led by Professor Gary Dmitrienko of the University Waterloo and
Professor Tim Walsh of the University of Cardiff will focus on hospital
acquired infections with the aim of developing a new treatment for
infections caused by bacteria resistant to beta-lactam antibiotics
(e.g., penicillin, carbapenems).
A team led by Professor Anthony Clarke of the University of Guelph and
Professor Chris Dowson of the University of Warwick will focus on
increasing our understanding of bacterial cell wall growth and
production with the aim of identifying new targets for the development
of new antibiotics.
"The UK Medical Research Council has made huge strides over the last
century to stem the tide of bacterial infection", says Professor Doreen
Cantrell, Chair of the Immunity and Infections Board at the Medical
Research Council. "We must remain one step ahead of bacterial
infections as they quickly learn how to combat drugs designed to beat
them. We're hopeful that the Canada /UK Partnership on Antibiotic
Resistance will add a new momentum to the work we have been carrying
out in the UK and Canada."
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's
mission is to create new scientific knowledge and to enable its
translation into improved health, more effective health services and
products, and a strengthened Canadian health care system. Composed of
13 Institutes, CIHR provides leadership and support to more than 14,100
health researchers and trainees across Canada.
For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by
supporting the highest quality science. The MRC invests in world-class
scientists. It has produced 29 Nobel Prize winners and sustains a
flourishing environment for internationally recognised research. The
MRC focuses on making an impact and provides the financial muscle and
scientific expertise behind medical breakthroughs, including one of the
first antibiotics penicillin, the structure of DNA and the lethal link
between smoking and cancer. Today MRC funded scientists tackle research
into the major health challenges of the 21st century.
SOURCE Canadian Institutes of Health Research
For further information:
Canadian Institutes of Health Research
Medical Research Council
020 7395 2276
For more information on the Canada/UK Partnership on Antibiotic Resistance, please contact:
Dr. Judith Bray
CIHR Institute of Infection and Immunity